FindTrial
Sign In

Phase II/III induction study of AJG501 in patients with active ulcerative colitis

Phase II/III induction study of AJG501 in patients with active ulcerative colitis

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080221110
Enrollment
Unknown
Registered
2010-05-25
Start date
2010-05-25
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative colitis

Interventions

investigational material(s) Generic name etc : AJG501 INN of investigational material : Therapeutic category code : 239 Other agents affecting digestive organs Dosage and Administration for Investiga

Sponsors

Ajinomoto Pharmaceuticals Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Baseline Revised Sutherland DAI score of 4-8 including abnormal rectal bleeding score

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Change in Revised Sutherland DAI Revised Sutherland DAI—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026